MOTS-c Compounding Pharmacy: How to Read a Certificate of Analysis

What Is MOTS-c and Why Does COA Quality Matter?

MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded in the 12S rRNA gene of mitochondrial DNA. Its molecular weight is approximately 2,173 Da. Early research published in Cell Metabolism by Lee et al. (2015) identified it as a regulator of insulin sensitivity and metabolic homeostasis, and a 2021 follow-up in Nature Communications by Lu et al. Described age-related declines in circulating MOTS-c levels in humans [1][2].

Because MOTS-c is not an FDA-approved drug, every vial dispensed in the United States comes from a compounding pharmacy. That means quality assurance rests almost entirely on the COA. A certificate that is missing key panels, produced by a non-accredited lab, or simply fabricated offers zero protection to the patient.

The Regulatory Gap That Makes the COA Essential

The FDA does not pre-approve compounded peptides. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy may compound MOTS-c for an individual patient based on a valid prescription [3]. Under Section 503B, an outsourcing facility may compound larger batches without patient-specific prescriptions but must comply with Current Good Manufacturing Practice (CGMP) [3].

The FDA has issued multiple warning letters to compounding pharmacies for failing to meet sterility or identity standards. A 2023 FDA warning letter database search confirms ongoing enforcement actions against peptide compounders that lacked adequate COA documentation [4]. Without a rigorous COA, the prescriber and patient cannot distinguish a compliant vial from one that is sub-potent, contaminated, or entirely mislabeled.

What PCAB Accreditation Signals

The Pharmacy Compounding Accreditation Board (PCAB) awards accreditation to pharmacies that voluntarily meet quality standards beyond state board minimums. PCAB-accredited facilities must follow USP <797> for sterile preparations and USP <795> for non-sterile ones, maintain documented standard operating procedures, and pass on-site audits. Choosing a PCAB-accredited pharmacy does not guarantee a perfect COA, but it does mean an independent body has reviewed the facility's quality systems.

The Six Panels Every MOTS-c COA Must Include

A credible COA is not a single number. It is a structured document covering identity, purity, safety, and stability. Each panel answers a different question about the vial in your patient's hands.

Panel 1: Identity Confirmation by Mass Spectrometry

Mass spectrometry (MS) confirms the peptide sequence and molecular weight. For MOTS-c, the expected monoisotopic mass is approximately 2,173.2 Da. The COA should display the observed m/z value and confirm it matches the theoretical value within the instrument's tolerance, typically ±0.1 Da for a high-resolution instrument.

Without MS data, HPLC purity alone cannot distinguish MOTS-c from a different peptide of similar size. A pharmacy that provides only HPLC without MS has not confirmed what molecule is actually in the vial.

Panel 2: HPLC Purity

High-performance liquid chromatography separates the peptide from synthesis byproducts, truncated sequences, and degradation products. The resulting chromatogram shows peaks as percentages of total area. For a clinical-grade peptide, MOTS-c purity should be 98% or higher by reverse-phase HPLC. Research published using synthetic MOTS-c in rodent models consistently uses material at this purity threshold or above [1].

Check the chromatogram, not just the summary number. A reputable COA includes the raw trace so that a qualified reviewer can confirm no large impurity peaks are hidden below a 1% reporting threshold.

Panel 3: Endotoxin Testing

Endotoxins are bacterial lipopolysaccharide fragments that survive sterilization and cause pyrogenic reactions in patients. USP <85> specifies the Limulus Amebocyte Lysate (LAL) method for endotoxin quantification [5]. For parenterally administered peptides, the FDA's general guidance on large-volume parenterals sets an endotoxin limit of 0.5 EU/mL; for smaller-volume injectables compounded for individual patients, the accepted limit is often cited at <2.0 EU/mg of active ingredient.

The COA must display a numeric result, not merely "pass." If the lab reports only "NMT 2.0 EU/mg, PASS," ask the pharmacy for the actual measured value. A result of 0.08 EU/mg is very different from 1.95 EU/mg even if both technically pass.

Panel 4: Sterility Testing per USP <71>

USP <71> sterility testing cultures the compounded preparation under conditions that detect aerobic bacteria, anaerobic bacteria, and fungi over a 14-day incubation period [6]. The COA should state the method used (direct inoculation or membrane filtration), the incubation period, the media used (Fluid Thioglycollate Medium and Soybean-Casein Digest Medium), and the result.

A result of "No growth detected after 14 days" is the acceptable outcome. Any pharmacy reporting sterility from a 7-day test or a non-USP method should be questioned directly.

Panel 5: Moisture and Residual Solvents

Lyophilized (freeze-dried) MOTS-c vials should have a moisture content below 8% by Karl Fischer titration, per USP <921> [6]. Excess moisture accelerates degradation and shortens shelf life. Residual solvent testing under USP <467> confirms that solvents used during synthesis, such as acetonitrile or dimethylformamide, have been removed to safe limits.

These panels are often omitted by lower-quality suppliers. Their absence does not mean the product is unsafe, but it does mean the pharmacy has chosen not to verify it.

Panel 6: Peptide Content and Potency by Amino Acid Analysis

Amino acid analysis (AAA) hydrolizes the peptide into individual amino acids and quantifies them by chromatography to confirm the total peptide content per vial. This answers the potency question: does a vial labeled "10 mg MOTS-c" actually contain 10 mg? Underdosed peptides waste money; overdosed ones create unpredictable dosing.

The COA should show the labeled amount and the measured amount. Acceptable variance for a compounded preparation is typically ±10% of label claim, consistent with USP general chapters on assay requirements [6].

How to Verify the Lab Behind the COA

A COA is only as trustworthy as the laboratory that produced it. Here is the HealthRX four-step verification framework for any MOTS-c COA:

Step 1. Confirm ISO 17025 accreditation. The testing laboratory must hold ISO/IEC 17025 accreditation for the specific test methods listed on the COA. In the United States, labs accredited by A2LA (American Association for Laboratory Accreditation) or NVLAP publish searchable directories online. Look up the lab name before trusting the numbers.

Step 2. Check that the lab is independent. In-house testing by the pharmacy itself is not acceptable for sterility or endotoxin panels. An independent contract laboratory removes the conflict of interest that arises when a pharmacy tests its own product.

Step 3. Match the lot number on the COA to your vial. Every vial should be labeled with a lot number. That number must appear on the COA. A generic COA with no lot number attached to a specific vial is a fabricated document.

Step 4. Review the date. Beyond-use dating under USP <797> for compounded sterile preparations ranges from 12 hours at room temperature to 180 days frozen depending on the facility's sterility testing program [7]. Confirm that the preparation has not exceeded its beyond-use date and that the COA was generated for the specific lot, not recycled from an older batch.

The FDA's Drug Supply Chain Security Act (DSCSA) also requires pharmacies to maintain traceability records for drug products they dispense [8]. A pharmacy that cannot produce lot-specific documentation on request may be non-compliant with DSCSA.

The Regulatory and Legal Framework for MOTS-c in the United States

503A vs. 503B: What the Distinction Means for Quality

Under 503A of the FD&C Act, a compounding pharmacy fills prescriptions for individual patients [3]. These pharmacies are regulated primarily by state boards of pharmacy and are exempt from CGMP requirements, though they must comply with USP compounding standards. Under 503B, outsourcing facilities must register with the FDA, comply with CGMP, and submit adverse event reports [3].

For the prescriber, 503B facilities generally carry a higher quality floor because of CGMP oversight. For the patient, the practical difference shows up in the COA: 503B facilities are more likely to include complete sterility and endotoxin panels because FDA inspectors check for them during site visits.

State Board Oversight

Every state board of pharmacy maintains its own rules for compounding. Texas, for example, requires pharmacies compounding sterile preparations to hold a Class A-S permit and comply with USP <797> [9]. California similarly requires a sterile compounding license. A pharmacy shipping MOTS-c across state lines must comply with the receiving state's rules as well as its own.

Before purchasing, verify that the pharmacy holds an active license in your state. Most state boards publish license verification tools online.

FDA Warning Letters as a Quality Signal

The FDA publishes all warning letters on its website. Searching fda.gov for warning letters to compounding pharmacies reveals enforcement actions for failures including non-sterile conditions, inaccurate labeling, and lack of potency testing [4]. A pharmacy that has received a warning letter related to sterile peptides within the past three years warrants extra scrutiny, or avoidance.

What "Research Grade" Actually Means

Some online suppliers sell MOTS-c labeled "for research use only" or "not for human use." These products are generally produced without USP <797> oversight, may not have undergone sterility testing, and are typically sold without a prescription or physician involvement.

A 2020 analysis published in the Journal of Pharmaceutical and Biomedical Analysis tested commercially available "research-grade" peptides and found that 42% failed to meet the labeled purity or identity claims [10]. Using such material in humans carries real risk: sub-potent doses fail to produce the intended effect, while contaminated or mislabeled vials may cause harm.

The appropriate channel for MOTS-c in a clinical context is a PCAB-accredited or 503B-registered compounding pharmacy with a complete, lot-specific COA from an ISO 17025-accredited laboratory.

Practical Checklist: What to Ask Your Pharmacy

A prescribing clinician or an informed patient should ask every compounding pharmacy these specific questions before the first order:

• Can you provide a lot-specific COA for each vial, not a blanket document?
• Is the COA generated by an independent, ISO 17025-accredited laboratory?
• Does the COA include HPLC purity, MS identity confirmation, LAL endotoxin, USP <71> sterility, and amino acid analysis?
• What is the beyond-use date assigned under your sterility testing program?
• Are you PCAB-accredited and licensed as a sterile compounder in my state?
• Have you received any FDA warning letters in the past three years related to sterile compounding?

A pharmacy that answers all six questions clearly and provides documentation is operating at a standard consistent with USP <797> and reasonable clinical expectations. One that deflects, provides generic answers, or cannot produce a lot-specific COA should not be used for injectable peptides.

Reading the COA: A Line-by-Line Walkthrough

Below is how to interpret each field you will actually see on a real MOTS-c COA.

Header Fields

The top of the COA should display the pharmacy or manufacturer name, address, contact information, the lot number, the manufacturing date, the beyond-use date, and the testing laboratory's name and accreditation number. If any of these fields are blank, ask for a corrected document.

Results Table

The results table typically lists each test method, the specification (the acceptance criterion), and the actual result. A compliant COA might read:

| Test | Method | Specification | Result | |---|---|---|---| | Appearance | Visual | White lyophilized powder | Conforms | | Identity (MS) | ESI-MS | 2173.2 ±0.2 Da | 2173.1 Da | | Purity (HPLC) | RP-HPLC | ≥98.0% | 99.2% | | Endotoxin | USP <85> LAL | <2.0 EU/mg | 0.12 EU/mg | | Sterility | USP <71> | No growth | No growth | | Moisture | USP <921> | ≤8.0% | 2.4% | | Peptide Content | AAA | 90.0 to 110.0% | 102.3% |

Every column must be populated. A COA that lists specifications without corresponding results is incomplete and unacceptable.

Signatures and Release Statement

The COA should be signed (electronically or physically) by a qualified person at the testing laboratory, with a date. A release statement confirms that the lot meets all specifications and is approved for dispensing. Without a release statement, the COA is a preliminary draft, not a final quality document.

Where to Buy MOTS-c: Summary Guidance

The short answer: buy only from a PCAB-accredited or FDA-registered 503B outsourcing facility, with a valid prescription, and request a complete lot-specific COA before accepting any shipment. Do not purchase from online research chemical suppliers, regardless of price.

The FDA maintains a list of registered outsourcing facilities at fda.gov [11]. Cross-reference any pharmacy you are considering against that list. If the pharmacy does not appear, it is not a 503B facility and carries the quality limitations of a 503A compounder, which may still be acceptable if it is PCAB-accredited and state-licensed for sterile compounding.

Pricing that seems dramatically lower than competitors is often a signal of cut corners: shorter sterility testing windows, cheaper raw peptide with lower purity, or in-house COA fabrication. MOTS-c synthesis at 98%+ purity with full analytical panels costs real money. A vial priced at a fraction of market rate has almost certainly not been manufactured and tested to clinical standards.